Get the Stockscreener App
0.4318
1.53%
-0.0067
After Hours:
.44
0.0082
+1.90%
Outlook Therapeutics Inc stock is traded at $0.4318, with a volume of 712.45K.
It is down -1.53% in the last 24 hours and up +10.72% over the past month.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
See More
Previous Close:
$0.4385
Open:
$0.435
24h Volume:
712.45K
Relative Volume:
0.14
Market Cap:
$31.74M
Revenue:
-
Net Income/Loss:
$-51.50M
P/E Ratio:
-0.108
EPS:
-4
Net Cash Flow:
$-47.10M
1W Performance:
-0.35%
1M Performance:
+10.72%
6M Performance:
-53.82%
1Y Performance:
-71.21%
1-Day Range:
$0.42
$0.4544
1-Week Range:
$0.404
$0.4544
52-Week Range:
$0.3801
$3.39
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Name
Outlook Therapeutics Inc
Sector
Industry
Phone
(609) 619-3990
Address
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
0.4318 | 32.23M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-25 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-02-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Mar-27-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-15-24 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-25-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-27-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Aug-31-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-31-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-30-23 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-30-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Aug-30-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Aug-30-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-13-23 | Initiated | CapitalOne | Overweight |
| Apr-03-23 | Initiated | Guggenheim | Buy |
| Feb-06-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-22 | Initiated | BTIG Research | Buy |
| Sep-13-22 | Initiated | Chardan Capital Markets | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| May-16-19 | Initiated | Oppenheimer | Outperform |
| Apr-22-19 | Initiated | Ascendiant Capital Markets | Buy |
View All
Outlook Therapeutics Inc Stock (OTLK) Latest News
Outlook Therapeutics discusses FDA meeting on bevacizumab drug - Investing.com India
First bevacizumab eye drug? Outlook, FDA discuss path for ONS-5010 - Stock Titan
Can Outlook Therapeutics Inc reach all time highs this yearJuly 2025 Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Risk On: Will Outlook Therapeutics Inc benefit from AI trendsJuly 2025 Spike Watch & Precise Buy Zone Identification - baoquankhu1.vn
OTLK Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Buyback Watch: Is Old Point Financial Corporation a good ESG investment2025 EndofYear Setup & Daily Profit Focused Screening - baoquankhu1.vn
OTLKW News Today: Stay Updated with the Latest Outlook Therapeutics, Inc.Se News in Real Time - Meyka
Aug Macro: Will Outlook Therapeutics Inc benefit from government policyMarket Sentiment Summary & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Key facts: Outlook Therapeutics Faces Nasdaq Compliance Deadline; Signs Deal with Mediconsult AG - TradingView
Outlook Therapeutics Signs Exclusive Distribution Deal With Mediconsult for Lytenava - marketscreener.com
Outlook Therapeutics (OTLK) Secures Swiss Distribution Deal for Lytenava - GuruFocus
Outlook Therapeutics, Inc. accelerates its European market expansion plan through partnerships, with its innovative drug Lytenava expected to officially enter the Swiss market in 2027. - Bitget
Can Outlook Break The Cycle With Fresh FDA Meeting On Ophthalmic Bevacizumab? - Citeline News & Insights
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland - The Manila Times
Outlook Therapeutics, Inc. accelerates its European market expansion plans through partnerships, with its innovative drug Lytenava expected to officially enter the Swiss market in 2027. - Bitget
Outlook Therapeutics Reports Q1 Fiscal Year 2026 Financial Results - VisionMonday.com
Outlook Therapeutics (OTLK) Maintains Neutral Rating According t - GuruFocus
Outlook Therapeutics Faces Nasdaq Minimum Bid Price Noncompliance - TipRanks
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA (bevacizumab gamma) in Switzerland - Bitget
Outlook Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Key facts: Outlook Therapeutics reports $1.2M loss; LYTENAVA launched in Europe - TradingView
OTLK: Analyst Maintains Neutral Rating and Price Target | OTLK S - GuruFocus
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update - The Globe and Mail
Outlook Therapeutics, Inc. SEC 10-Q Report - TradingView
OTLK: Net loss of $23.1M, negative revenue, and liquidity risks amid delayed US approval for LYTENAVA - TradingView
Outlook Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025 - marketscreener.com
OTLK: European sales of LYTENAVA doubled, but US approval for ONS-5010 remains uncertain - TradingView
Outlook Therapeutics swings to Q1 net loss - TradingView
Outlook Therapeutics Advances LYTENAVA™ Expansion in Europe with Launch Scheduled for Austria and Regulatory Update for ONS-5010 in the U.S. - Quiver Quantitative
Outlook Therapeutics Earnings Report: Q1 Overview - Benzinga
Published on: 2026-02-16 11:51:16 - mfd.ru
Sell Signal: Can Outlook Therapeutics Inc. stock maintain growth trajectoryDay Trade & Free Accurate Trade Setup Notifications - mfd.ru
OTLK Stock Price, Forecast & Analysis | OUTLOOK THERAPEUTICS INC (NASDAQ:OTLK) - ChartMill
Outlook Therapeutics Seeks FDA Meeting on ONS-5010 BLA - The Globe and Mail
SPHERA FUNDS MANAGEMENT LTD. Acquires Significant Stake in Outlo - GuruFocus
Key facts: Outlook Therapeutics Seeks FDA Meeting on ONS-5010 Issues - TradingView
IPO Launch: What drives Renasant Corporations stock priceQuarterly Earnings Summary & Daily Growth Stock Tips - baoquankhu1.vn
Outlook Therapeutics submits Type A meeting request to FDA following Complete Response Letter - marketscreener.com
Outlook Therapeutics Submit Type A Meeting Request To FDA Following CRL - Nasdaq
Outlook Therapeutics Submits Type A Meeting Request To FDA Following Complete Response Letter - TradingView
Outlook Therapeutics (OTLK) Faces FDA Request for Additional Evi - GuruFocus
Outlook Therapeutics seeks FDA meeting after response letter - Traders Union
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter - GlobeNewswire
Risk Check: Is Outlook Therapeutics Inc a top pick in the sectorEarnings Beat & Technical Confirmation Alerts - baoquankhu1.vn
Decliners Report: Can Outlook Therapeutics Inc reach all time highs this yearTrend Reversal & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
US Market Recap: Should you buy the dip on Outlook Therapeutics IncAnalyst Upgrade & Safe Entry Trade Reports - baoquankhu1.vn
Outlook Therapeutics Is Suddenly Everywhere – Is This Tiny Eye-Drug Stock a Sleeping Monster or Ju - AD HOC NEWS
Is Outlook Therapeutics Inc stock a buy or sellJuly 2025 Decliners & Intraday High Probability Setup Alerts - baoquankhu1.vn
Can Outlook Therapeutics Inc. reach all time highs this yearJuly 2025 Review & Low Risk High Reward Trade Ideas - mfd.ru
Bull Run: Will Outlook Therapeutics Inc outperform the market in YEARWeekly Market Report & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Profit Recap: Can Manhattan Associates Inc expand into new markets2025 Earnings Impact & Long-Term Investment Growth Plans - baoquankhu1.vn
Outlook Therapeutics Inc Stock (OTLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):